FDA claims that Velcade mailer violates drug marketing law
This article was originally published in Scrip
Executive Summary
The US FDA has informed Takeda's Millennium Pharmaceuticals unit that its inclusion of a double-entendre around a cancer term "CR" in a mailer for Velcade (bortezomib) relating to the ASCO 2008 annual meeting in Chicago went beyond what is permitted in a reminder piece, and is thus violative of drug marketing law.